Results 61 to 70 of about 28,214,376 (236)
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley +1 more source
Kimberly Mislick,1 Warren Schonfeld,2 Carolyn Bodnar,3 Kuo Bianchini Tong2 1Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, USA; 2Quorum Consulting, Inc, San Francisco, CA, USA; 3GE Healthcare, Chalfont St Giles, Buckinghamshire, UK Purpose ...
Mislick K +3 more
doaj
Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley +1 more source
Using Cost Effectiveness Analysis; a Beginners Guide
Objective - To describe the key elements of cost effectiveness analysis (CEA) and demonstrate how such analysis may be used in the library environment.
Claire Hulme
doaj +3 more sources
Barry Weinstock,1 Raymond Dattilo,2 Tiffini Diage3 1Orlando Health Heart Institute, Mid-Florida Cardiology Specialists, Orlando, FL, USA; 2Department of Cardiology, St Francis Health Center, Topeka, KS, USA; 3North American Science Association (NAMSA ...
Weinstock B, Dattilo R, Diage T
doaj
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.
Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.
Frauke Becker (2836922) +11 more
core +1 more source
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou +4 more
wiley +1 more source
Cost-effectiveness of glaucoma management with monotherapy medications in Egypt
Glaucoma is a serious chronic ophthalmic disease since it causes irreversible visual disability if untreated can lead to blindness. Treatment options include medications (classified into five major classes of drugs which are muscarinic cholinergic ...
Amal Abd-Elaal El-Khamery +3 more
doaj +1 more source
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source

